Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mark Löwenberg
Sa1478 HISTONE SEROTONYLATION: THE HIDDEN EPIGENETIC KEY TO SEVERE FATIGUE IN CROHN’S DISEASE?
This paper is only available as a PDF . Get full text access Log in, subscribe or purchase for full access.
Sa1495 COMPREHENSIVE DISEASE CONTROL WITH VEDOLIZUMAB IS MORE OFTEN ATTAINED IN EARLY THAN LATE CROHN’S DISEASE
Also available on ScienceDirect
Sa1496 SOLID INDEPENDENT VALIDATION OF A CLINICAL DECISION SUPPORT TOOL FOR THE PREDICTION OF DEEP REMISSION IN CROHN’S DISEASE: DATA FROM LOVE-CD
Also available on ScienceDirect
Improving Power Generation in Rigid‐Wing Groundgen Airborne Wind Energy Systems Using Feedback Control-A Parametric Study
1 Introduction Airborne wind energy systems (AWES) are an emerging technology for electricity generation using tethered flying devices. Compared to traditional wind turbines, AWES are easy to transport and use less material over their lifetime. This means AWES can provide clean energy in areas where construction of wind turbines is not feasible. Research into AWES has grown significantly in the past two decades, with research groups and startups proposing increasingly innovative designs.
FAPi PET/CT Imaging to Identify Fibrosis in Immune-Mediated Inflammatory Diseases
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Diagnostics | Free Full-Text | Validation Study of Novel Point-of-Care Tests for Infliximab, Adalimumab and C-Reactive Protein in Capillary Blood and Calprotectin in Faeces in an Ambulatory Inflammatory Bowel Disease Care Setting
Altmetric share Share announcement Help format_quote Cite thumb_up ... Endorse textsms ... Comment Need Help? Support Find support for a specific problem in the support section of our website. Get Support Feedback Please let us know what you think of our products and services. Give Feedback Information Visit our dedicated information section to learn more about MDPI.
Vedolizumab for the Treatment of Chronic Pouchitis
This article is available to subscribers. Subscribe now. Already have an account? Sign in Original ArticleFree Preview List of authors. Simon Travis, D.Phil., Mark S. Silverberg, M.D., Ph.D., Silvio Danese, M.D., Ph.D., Paolo Gionchetti, M.D., Mark Löwenberg, M.D., Ph.D., Vipul Jairath, M.B., Ch.B., D.Phil., Brian G.
COMMUNITY-ACQUIRED BACTERIAL MENINGITIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
Inflammatory bowel diseases (IBD), ulcerative colitis and Crohn's disease, are chronic inflammatory disorders of the gastrointestinal tract. Higher incidence of common infections has been reported in IBD patients compared to matched controls (). Here, we report characteristics of IBD patients with community-acquired bacterial meningitis that were identified in a large nationwide observational cohort study and performed a review of the literature.
A rare cause of acute abdominal pain after endoscopic retrograde cholangiopancreaticography
Mitch van Dijk, BSc Mitch van Dijk Correspondence Corresponding author: M van Dijk, BSc Contact information Phone number(mobile): +31629347218 Affiliations Amsterdam University Medical Centers , Meibergdreef 9, Amsterdam, The Netherlands Search for articles by this author Tassili A.F. Weehuizen, MD PhD Mark Löwenberg, MD PhD This paper is only available as a PDF. To read, Please Download here.
Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease-a prospective multicentre cohort study - Asscher - - Alimentary Pharmacology & Therapeutics - Wi
Summary Background Few data are available on the effects of age and comorbidity on treatment outcomes of vedolizumab and ustekinumab in inflammatory bowel disease (IBD). Aims To evaluate the association between age and comorbidity with safety and effectiveness outcomes of vedolizumab and ustekinumab in IBD. Methods IBD patients initiating vedolizumab or ustekinumab in regular care were enrolled prospectively. Comorbidity prevalence was assessed using the Charlson Comorbidity Index (CCI).
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
Summary Background Both vedolizumab and ustekinumab can be considered for the treatment of Crohn’s disease (CD) when anti‐TNF treatment fails. However, head‐to‐head trials are currently not available or planned. Aim To compare vedolizumab and ustekinumab in Crohn´s disease patients in a prospective registry specifically developed for comparative studies with correction for confounders.
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
Summary Background Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). Aim To evaluate effectiveness, safety and use of tofacitinib in daily practice. Methods UC patients initiating tofacitinib were prospectively enrolled in 15 hospitals in the Netherlands.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mark
Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack